Albert Lowe
Stock Analyst at Craig-Hallum
(3.86)
# 1,908
Out of 5,022 analysts
146
Total ratings
43.5%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Reiterated: Buy | $68 | $29.20 | +132.88% | 2 | Sep 30, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $140 | $45.71 | +206.28% | 4 | Sep 30, 2026 | |
| RZLT Rezolute | Upgraded: Buy | $4 → $7 | $4.01 | +74.56% | 16 | Sep 29, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $8 | $0.8567 | +833.82% | 7 | Sep 23, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $1.12 | - | 14 | Sep 15, 2026 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | n/a | $0.9303 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | n/a | $4.58 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $132.47 | +54.75% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $6 | $2.98 | +101.34% | 10 | Jun 16, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $65 | $25.65 | +153.41% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $12 | $0.819 | +1,365.20% | 9 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.92 | $10.32 | +93.02% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.24 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.68 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.34 | +327.35% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.49 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.52 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.79 | +123.46% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.92 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $337.04 | n/a | 1 | Jun 4, 2024 |
Quince Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: $68
Current: $29.20
Upside: +132.88%
Spruce Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $140
Current: $45.71
Upside: +206.28%
Rezolute
Sep 29, 2026
Upgraded: Buy
Price Target: $4 → $7
Current: $4.01
Upside: +74.56%
Compass Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $8
Current: $0.8567
Upside: +833.82%
Cardiff Oncology
Sep 15, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.12
Upside: -
Lineage Cell Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.9303
Upside: -
Opus Genetics
Jul 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.58
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $132.47
Upside: +54.75%
SAB Biotherapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $6
Current: $2.98
Upside: +101.34%
Neurogene
May 15, 2026
Reiterated: Buy
Price Target: $65
Current: $25.65
Upside: +153.41%
May 12, 2026
Reiterated: Buy
Price Target: $25 → $12
Current: $0.819
Upside: +1,365.20%
May 5, 2026
Reiterated: Buy
Price Target: $19.92
Current: $10.32
Upside: +93.02%
Apr 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.24
Upside: -
Mar 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.68
Upside: -
Feb 12, 2026
Reiterated: Buy
Price Target: $10
Current: $2.34
Upside: +327.35%
Jan 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.49
Upside: -
Jan 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.52
Upside: -
Nov 13, 2025
Reiterated: Buy
Price Target: $4
Current: $1.79
Upside: +123.46%
Jun 6, 2024
Reiterated: Buy
Price Target: n/a
Current: $6.92
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $337.04
Upside: n/a